Mylan gets FDA approval for generic Keppra

11/5/2008 | Boston Globe (tiered subscription model), The

Mylan secured FDA clearance to sell levetiracetam, a copy of UCB's epilepsy medicine Keppra. Mylan has begun shipments of the product, which are available in 250-mg, 500-mg and 750-mg tablets. UCB retains exclusive rights to market Keppra for pediatric use until it loses U.S. patent protection in January.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN